Thomas Weisel starts coverage of Indenix at peer perform

Thomas Weisel Partners analyst Joe Slavinsky gave Indenix Pharmaceuticals, Inc. a peer perform rating based on valuation. Indenix continues to move forward with its New Drug Application for hepatitis B virus, with Novartis, and with testing of other hepatitis B and HIV products. Shares of the Cambridge, Mass., biopharmaceutical company were up 3 cents, or 0.15%, at $20.50 on volume of 477,670 shares versus the three-month running average of 335,446 shares. (Nasdaq: IDIX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.